News coverage about Arbutus Biopharma (NASDAQ:ABUS) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.4875665812592 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 Earnings Per Share (americanbankingnews.com)
- Arbutus Biopharma (ABUS) Upgraded to “Hold” by Zacks Investment Research (americanbankingnews.com)
- Wedbush Weighs in on Arbutus Biopharma’s Q1 2018 Earnings (ABUS) (americanbankingnews.com)
- Edited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMT (finance.yahoo.com)
- Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT (finance.yahoo.com)
ABUS has been the subject of a number of research reports. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. ValuEngine downgraded Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. Finally, B. Riley initiated coverage on Arbutus Biopharma in a research note on Friday, January 5th. They issued a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $12.38.
Arbutus Biopharma (NASDAQ:ABUS) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. The company had revenue of $2.50 million during the quarter, compared to analyst estimates of $0.70 million. analysts anticipate that Arbutus Biopharma will post -1.7 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma (ABUS) Given Media Impact Score of 0.01” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3296596/arbutus-biopharma-abus-given-media-impact-score-of-0-01.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.